Who
Nur Nicholson
Chief Technology Officer
Company insider
Files Form 4 as: Chief Technology Officer, Kailera Therapeutics; Chief Technical Officer, Apellis Pharmaceuticals.
In numbers
- Trades disclosed
- 81
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $2.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 28 Jan 2021
- Last trade
- 7 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Sep 2026filed 9 Sep 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 7 Sep 2026filed 9 Sep 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —116,338 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —5,645 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —9,754 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —27,320 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —45,220 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —115,281 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,974 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —35,472 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,367 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,610 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —22,610 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —115,281 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —50,974 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —35,472 | filing |
News
No headline names them, or the companies they trade most, lately.